Cytosolic phospholipase A 2 (cPLA 2 ) catalyzes the selective release of arachidonic acid from the sn-2 position of phospholipids and is believed to play a key cellular role in the generation of arachidonic acid. When assaying the human recombinant cPLA 2 using membranes isolated from [ 3 H]arachidonate-labeled U937 cells as substrate, 2-(2-benzyl-4-chlorophenoxy)ethyl-dimethyln-octadecyl-ammonium chloride (compound 1) was found to inhibit the enzyme in a dose-dependent manner (IC 50 ‫؍‬ 5 M). It was over 70 times more selective for the cPLA 2 as compared with the human nonpancreatic secreted phospholipase A 2 , and it did not inhibit other phospholipases. Additionally, it inhibited arachidonate production in N-formyl-methionyl-leucyl-phenylalanine-stimulated U937 cells. To further characterize the mechanism of inhibition, an assay in which the enzyme is bound to vesicles of 1,2-dimyristoyl-sn -glycero-3-phosphomethanol containing 6 -10 mol % of 1-palmitoyl-2-[1-
The hydrolysis of the sn-2 arachidonoyl ester of phospholipids is catalyzed by a phospholipase A 2 . Because of its apparent role in the generation of leukotrienes and prostaglandins, potent inflammatory mediators metabolized from arachidonate, phospholipases A 2 have received considerable medicinal interest. Several different forms of the enzyme have been identified; the best characterized are the 85-kDa cytosolic enzyme (cPLA 2 ), 1 the 14-kDa secreted enzyme (sPLA 2 ), and a calciumindependent enzyme (CaI-PLA 2 ) found in myocardial tissue (for reviews, see Refs. [1] [2] [3] .
cPLA 2 is a calcium-dependent enzyme that is present in a number of different tissues and cells, including monocytes, neutrophils, and platelets (4, 5, 6) . Unlike the sPLA 2 , this enzyme has been shown to be selective for arachidonate-containing phospholipids (7, 8) . The enzyme is normally located in the cytosol but translocates to the membrane in response to submicromolar concentrations of calcium (9, 10) . Modulation of cPLA 2 activity by the bilayer composition, either through a cooperative binding mechanism with arachidonate-containing phospholipids (11) or through phosphatidylinositol 4,5-bisphosphate binding to a pleckstrin homology domain (12) , may account for another mechanism of regulation in vivo.
The catalytic mechanism of cPLA 2 is thought to be much like that of serine esterases and proteases: the enzyme forms an acyl enzyme intermediate between arachidonate of the phospholipid substrate and an active site serine residue. Site-directed mutagenesis has been used to provide evidence that serine 228 is this putative active site nucleophile (13, 14) . Other evidence for this mechanism comes from the observation that the enzyme also catalyzes, to a small extent, a transacylase reaction, which is most simply explained by invoking an acyl enzyme intermediate (15, 16) . Additionally, the arachidonoyltrifluoromethyl ketone, a potent inhibitor of the enzyme, shows kinetic and spectroscopic characteristics with the enzyme that are consistent with the formation of a hemiketal with a serine residue in the active site (17, 18) . The presence of glycerol, which enhances the activity of the enzyme (11, 19) , results in the formation of monoarachidonoyl glycerol, which further demonstrates that the enzyme possesses a transacylase activity (16) .
Because the phospholipid substrate on which the enzyme acts is in the form of an aggregate rather than water soluble monomers, the enzyme must first bind to the surface of the lipid-water interface before a phospholipid molecule can bind to the active site (20) . To accomplish this interfacial binding step, the enzyme contains a calcium-dependent interfacial binding site, separate from the active site, that is responsible for the translocation of the enzyme to the interface. The location of this interfacial binding site is the N terminus of the enzyme (10, 21) . This portion of the enzyme has significant sequence homology to the lipid binding domains of both protein kinase C and phospholipase C ␥1 (10) .
The interfacial binding step has presented a great challenge when performing kinetic analyses of the enzyme. However, the analysis of phospholipase catalysis at the interface has received considerable investigation and has led to kinetic schemes describing the action of phospholipases (22, 23) . The kinetics can be described using classical Michaelis-Menten kinetic theory applied to interfacial catalysis (24) , which facilitates determination of numerous kinetic parameters and binding constants (11, 25) .
In this paper, we provide a detailed characterization of the inhibition of cPLA 2 by analogs of 2-(2Ј-benzyl-4-chlorophenoxy)-ethyl-dimethyl-n-octadecyl-ammonium chloride (compound 1). This compound is shown to act by inhibiting the enzyme at the lipid-water interface. That is, the inhibitor partitions into the bilayer and competes with phospholipid monomers for the active site of the enzyme. Additionally, important information regarding potential in vivo efficacy of these compounds was gleaned from the inhibition observed using analogs of compound 1 with shorter n-alkyl chains.
EXPERIMENTAL PROCEDURES

Materials
All nonradiolabeled phospholipids were obtained from Avanti Polar Lipids except for DMPM, which was from Calbiochem. The radiolabeled 14 C-PAPC was from NEN Life Science Products (55 mCi/mmol). The human, premonocytic U937 cell line was obtained from the American Type Culture Collection. [ 3 H]Arachidonate-labeled U937 membranes were prepared from U937 cells that had been prelabeled with [ 3 H]arachidonate (100 Ci/mmol) as described previously (26) .
The human, recombinant cPLA 2 was expressed in Sf9 insect cells and highly purified as described previously (11) . The human nonpancreatic sPLA 2 (group IIA), which had been purified from human platelets according to the procedure of Raghupathi and Franson (27) , was obtained from Dr. R.C. Franson (Virginia Commonwealth University) along with the [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]oleic acid-labeled Escherichia coli membrane substrate (3000 dpm/nmol phospholipid).
Enzyme Assays
Sonicated phospholipid covesicles composed of DMPM and containing 14 C-PAPC or other phospholipids, were prepared using the general methods described previously (7, 28, 29) . With this synthetic substrate, enzymatic assays were performed using the general procedure of Burke et al. (11) in which cPLA 2 (210 -390 ng/ml) was added to solutions of the radiolabeled covesicles (150 -270 M bulk phospholipid) in 25 mM BisTris propane containing 7 mM CaCl 2 , 0.4 mg/ml albumin (bovine serum albumin, essentially fatty acid-free), and 4 M glycerol at pH 8. All components except enzyme were incubated at 37°C for 5 min before the addition of enzyme. At various times, 100-l aliquots were removed and quenched by addition into 1.9 ml tetrahydrofuran. The hydrolyzed, radiolabeled fatty acid was then isolated using aminopropyl solid-phase extraction columns as described previously (30) . The rate of hydrolysis was calculated after an initial burst of product formation (31) . Under these assay conditions, the high calcium concentration catalyzes vesicle fusion with continuous exchange of phospholipids (11, 32) .
Assays of cPLA 2 activity using the 3 H-arachidonate-labeled U937 membranes as substrate typically employed 0.6 g/ml enzyme and membrane substrate (22 M) in 20 mM HEPES buffer, pH 8, containing 6 mM CaCl 2 , 0.9 mg/ml human serum albumin and 0 -4 M glycerol (26) . Enzyme assays were allowed to proceed for 20 min at 37°C before quenching with tetrahydrofuran. The radiolabeled fatty acid product was isolated as described above.
Assays of sPLA 2 utilizing radiolabeled E. coli membrane as substrate were performed as described previously (30) .
Cell Assays For measurements of the effects of cPLA 2 inhibitors on cellular arachidonate production, dibutyryl-cAMP-differentiated U937 cells were used according to the previously published procedure (33) . In short, cells were preincubated with the inhibitors for 5 min at 37°C prior to stimulating with the chemotactic peptide, fMLP. After 5 min of stimulation, the reactions were terminated in an ice bath, and the mass of arachidonate determined by GC/electron capture of derivatized product (33) .
For the effect on the products of phospholipase C, the fMLP-induced production of inositol trisphosphates in these same cells was carried out as described previously. (33) .
Differential Scanning Calorimetry
Differential scanning calorimetry was performed with a MCS differential scanning calorimetry instrument (MicroCal Corp.) and software provided by the manufacturer. DMPM vesicles were prepared by evaporating a CHCl 3 stock solution of phospholipid in a glass tube under a N 2 stream and drying under high vacuum at room temperature for 4 h. If small molecules were incorporated into the bilayer at the time of vesicle formation, the compounds were dissolved in Me 2 SO and added to the CHCl 3 solution of phospholipids and evaporated to dryness. The thin films were rehydrated by adding 1.0 ml of H 2 O and vortexing, to obtain a final phospholipid concentration of 2 mM. Samples were frozen and stored at Ϫ20°C. To prepare vesicles, the frozen phospholipid samples were sonicated at room temperature in a laboratory bath sonicator for 10 -15 min, which resulted in optically transparent samples. Differential scanning calorimetry samples were prepared by diluting the phospholipid sample to 1 mM with 2ϫ buffer, yielding a final buffer composition of 25 mM Tris, pH 8.0, 50 mM KCl, 0.1 mM EDTA, and Me 2 SO containing the small molecule at the desired concentration (if added to preformed vesicles). Samples in which the small molecule was added during preparation of the bilayer contained no Me 2 SO. The reference cell was filled with 25 mM Tris, pH 8.0, 50 mM KCl, 0.1 mM EDTA, and an equal volume of Me 2 SO as appropriate (typically 2% v/v). All samples were degassed under vacuum with vigorous stirring for 10 min before loading into the instrument, and kept under 20 psi N 2 during the scans. Samples were scanned three times from 10 -50°C at a rate of 40°C/hr. Repetitive scans were superimposible in all cases. To obtain the final thermograms, a baseline was subtracted from each raw data set and then corrected for total phospholipid concentration to give the excess heat capacity (in cal/mol°C) versus temperature. To determine thermodynamic parameters Tm, ⌬H, and ⌬H vH , software provided by the manufacturer was used, fitting the thermograms to a single transition, which gave good fits in all cases.
Laser Light Scattering
Light scattering experiments were performed on a Dawn model F instrument (Wyatt Technology Corporation) and software provided by the manufacturer. Samples were analyzed using carefully washed glass scintillation vials and 25 mM Tris, pH 8, buffer filtered through 0.02 m Anotop filters (Whatman). Samples were thermostatted at 37°C. Stock solutions of small molecules were prepared at 100 M in anhydrous ethanol and centrifuged at 14,000 ϫ g for 10 min or alternatively filtered through 0.10 m Anotop filters to remove dust or other interfering insoluble material. Small volumes of a stock solution were added to the filtered buffer in a vial and equilibrated for 3 min before collecting data. Compounds were titrated typically from 10 -1500 nM by subsequent additions to a single vial. All light scattering titrations were done twice. This procedure was used to monitor the concentrations at which scattering intensities increased by ϭ 0.1 V at 90°detection, indicative of association, or alternatively slow precipitation. The concentration at which the scattering intensity increased and maintained a value of ϭ 0.1 V over background is reported in Table III for compounds 1, 2, 5, and 6. In no case was any visible precipitate or haziness visible by eye in the samples.
COMPOUND 1
Synthesis 2-(2Ј-Benzyl-4Ј-chlorophenoxy)ethyldimethyl-n-octadecyl-ammonium
Chloride (Compound 1)-2-(2Ј-Benzyl-4Ј-chlorophenoxy)ethyl dimethylamine (34) was alkylated with 1-iodooctadecane in isopropyl alcohol (35) (34) was alkylated with 1,2-dibromoethane to give 2-bromoethyl-(2Ј-benzyl-4Ј-chlorophenyl) ether. This was reacted with 1-dodecylamine to give 2-(2Ј-benzyl-4Ј-chlorophenoxy)ethyl-n-dodecylamine, which was converted with hydrogen chloride/ether solution to 2-(2Ј-benzyl-4Ј-chlorophenoxy)ethyl-n-dodecylamine hydrochloride (compound 5). NMR (CDCl 3 ): ␦ 9.6 (broad s, 2H), 7 2-(2Ј-Benzyl-4Ј-chlorophenoxy)ethyl-n-octylsulfoxide (Compound 6)-2-Benzyl-4-chloro-phenol was alkylated with 1,2-dibromo-ethane to 2-bromoethyl-(2Ј-benzyl-4Ј-chlorophenyl) ether. This was reacted with n-octanethiol to give thioether 2(2Ј-benzyl-4Ј-chlorophenoxy)ethyl noctylsulfide, which was in turn oxidized with m-chloroperoxy-benzoic acid to give sulfoxide 2-(2Ј-benzyl-4Ј-chlorophenoxy)ethyl n-octylsulfoxide (compound 6). H]arachidonate incorporate this radiolabeled fatty acid into phospholipid pools. An assay using membranes isolated from these radiolabeld U937 cells as substrate was used to measure the activity of human, recombinant cPLA 2 . When assayed in this manner, compound 1 was identified as an inhibitor of cPLA 2 . As shown in Fig. 1 , the dose-dependent inhibition gave an IC 50 value of 5 M.
2-(2Ј-Benzyl-4Ј-chlorophenoxy)ethyldimethyl-n-butyl-ammonium Iodide (Compound
2-(2Ј-Benzyl-4Ј-chlorophenoxy)ethyl-n-dodecylamine Hydrochloride (Compound 5)-2-Benzyl-4-chlorophenol
When tested against the group IIA sPLA 2 , Fig. 1 also shows the inhibition to be ϳ70 times less potent (IC 50 ϭ 340 M). Moreover, compound 1 did not inhibit phospholipase C, phospholipase A 1 , or phospholipase D (results not shown), further demonstrating the selectivity of inhibition for cPLA 2 . The compound was not tested against the calcium-independent phospholipase A 2 .
Inhibition of Arachidonate Production in Cells-Further evidence for the selectivity of compound 1 for cPLA 2 was obtained by using differentiated U937 cells. It has been shown that when these cells are stimulated with the chemotactic peptide fMLP, a robust release of arachidonate occurs. Moreover, this release is the result of the action of cPLA 2 (33) . fMLP stimulation of these cells also leads to the activation of phospholipase C with production of inositol 1,4,5-trisphosphate (33) .
As shown in Fig. 2 , compound 1 dose-dependently inhibited the fMLP-induced production of arachidonate in these cells (IC 50 ϭ 10 M) without affecting the production of inositol 1,4,5-trisphosphate. This demonstrates that compound 1 can act as a selective inhibitor of cPLA 2 within cells. It was also determined that compound 1 inhibits the production of arachidonate in LTB 4 -stimulated neutrophils and calcium ionophorestimulated platelets, yielding IC 50 values of 2 M (results not shown).
Mechanism of Inhibition of cPLA 2 -The equilibrium binding of cPLA 2 to the substrate involves a dependence on two processes as defined in Scheme 1 (11) These include the intrinsic equilibrium binding to the interface (defined by a dissociation constant, K S ) and the equilibrium binding of phospholipid substrate to the active site at the interface (defined by a dissociation constant, K m *), as follows, where E is defined as the free enzyme; A is the phospholipid vesicle; EA* is the enzyme bound to the lipid-water interface; S is the phospholipid substrate within the vesicle; and EAS* is the interface-bound enzyme containing an active-site-bound phospholipid substrate. A competitive, reversible inhibitor of cPLA 2 that acts at the lipid-water interface is a compound that associates with the phospholipid bilayer and binds to the active site of the enzyme when the enzyme is bound to the interface (11) . This type of inhibition is competitive: It competes with the individual phospholipids for the active site.
Definitive proof that compound 1 is acting as a competitive, reversible inhibitor at the lipid-water interface comes from the use of covesicles of 14 C-PAPC dispersed within DMPM. This covesicle substrate allows for the determination of the equilibrium dissociation constants of phosphopholipids and inhibitors from the active site at the interface (11) . The benefits of using this covesicle substrate system when performing kinetic analyses of inhibitors has recently been demonstrated (31) . Using these covesicles, the concentration of compound 1 was varied while measuring the cPLA 2 -catalyzed rate of hydrolysis of the covesicles containing different mol % of 14 C-PAPC. As long as the bulk phospholipid concentration is large enough to ensure that essentially all of the enzyme is at the interface (e.g. at 270 M phospholipid, over 98% of the enzyme is interface-bound; Ref. 11), the following equation describing competitive inhibition of cPLA 2 at the interface is valid (11, 37),
where
I is the ratio of initial rates in the absence to that in the presence of a competitive inhibitor; K m * app and K I * app are defined as the apparent dissociation constants for the substrate and inhibitor, respectively 3 ; X I is the concentration of inhibitor (in units of mole fraction); and X S o is the mole fraction of radiolabeled substrate ( 14 C-PAPC) in the absence of inhibitor. The unit of concentration in the interface is mole fraction, which is related to the surface concentration of substrate, rather than bulk concentration, which has units of molarity. With compound 1, the X I value was determined by assuming that all of the compound added was partitioned within the phospholipid bilayer (shown to be true later).
Using these covesicles as substrate for cPLA 2 , the dose-dependent inhibition by compound 1 was plotted in Fig. 3 (11, 37) .
Additional evidence that compound 1 is acting as a competitive, reversible inhibitor at the lipid-water interface comes from the use of covesicle substrate containing cholesterol (cholesterol:phospholipid ratio of 0.6:1). The presence of cholesterol in a phospholipid bilayer at this concentration has been shown to greatly reduce the partition coefficient of drugs into phospholipid bilayer vesicles (38, 39) . This results, presumably, from an increase in the packing density of the bilayer (40) Indeed, the results detailed in Fig. 4 show that the inhibition of cPLA 2 by compound 1 is greatly reduced when cholesterol is present in the covesicle substrate. This provides further support to the conclusion that compound 1 acts by partitioning into the phospholipid bilayer and competing with phospholipid monomers for the active site of cPLA 2 .
The assumption that the inhibitor was completely partitioned into the phospholipid bilayer of covesicle substrate (without cholesterol) was tested by determining the effect of reaction volume on the inhibition. If the inhibitor is completely partitioned into the vesicle, the degree of inhibition from a constant mole amount of inhibitor will be independent of the reaction volume as long as all of the enzyme is bound to the interface (41) . However, if the inhibitor is only partially parti- 2 This equation is valid because the active site dissociation constant for DMPM has been shown to be more than 330 times greater than the value for PAPC (see Ref. 37 ).
3 K M * app and K I * app are related to the intrinsic dissociation constants (K M * and K I *) by the following equations:
, where K L * is the active site dissociation constant for DMPM at the interface (see Ref. 37 ). 4 When determining the equilibrium dissociation constants from the active site, the mole amount of substrate ( 14 C-PAPC in this case) and the mole amount of DMPM were held constant while the mole amount of inhibitor was varied (see Refs. 11 and 37) . This has the effect of actually decreasing the mole fraction of both substrate and DMPM as the inhibitor concentration is increased. Thus, X S o in Equation 1 equals the mole fraction of substrate phospholipid without inhibitor. The mole fraction of substrate in the presence of the inhibitor is correspondingly less. tioned into the vesicle, the inhibition will decrease with increasing volume as more of the inhibitor partitions into the aqueous phase. Indeed, Table I shows that the inhibition of the linear rate was independent of the reaction volume. Therefore, all of compound 1 is partitioned into these covesicles of DMPM/ 14 C-PAPC under the assay conditions detailed in Fig. 3 , and the calculated K I * app value is accurate. Dependence of Inhibition on Alkyl Chain Length-The analog, compound 2, differs from compound 1 in that it contains an alkyl chain of 8 carbons as compared with the C-18 chain of compound 1. When tested using the covesicle substrate system described above, it was shown to be approximately a 5 times more potent inhibitor of cPLA 2 with a K I * app value of 0.02 mol % (results not shown). The inhibition by compound 2 was independent of the reaction volume, which indicates that it, like compound 1, is completely partitioned within this covesicle substrate.
However, when tested using the [ 3 H]arachidonate-labeled membranes from U937 cells as substrate, compound 2 appeared to be 2-3 times less potent than compound 1 (IC 50 values of 13 and 5 M, respectively). This discrepancy was reconciled by directly measuring the partitioning of these two compounds into the radiolabeled membranes from U937 cells. In this experiment, the concentration of membranes was varied while keeping the bulk concentration of inhibitor constant. As shown is Fig. 5 , the concentration of compound 1 in the aqueous phase decreased as the phospholipid concentration increased. A computer-generated fit of the data to partial partitioning (solid line) yielded a partition coefficient of 12,900. 5 The partitioning of compound 2, however, was much smaller (partition coefficient of ϳ1050). This is in contrast to the relative partitioning of the two inhibitors into the covesicle substrate, where both compound 1 and compound 2 were completely partitioned into the bilayer, and where the more effective inhibition by compound 2 reflects only the smaller K I * app value. With the U937 membrane substrate, however, compound 2 is partitioned ϳ10 times less effectively than compound 1. Therefore, the bilayer concentration of compound 2 is much less than that of compound 1 at the same bulk concentration of inhibitor, and this leads to less potent inhibition with compound 2 using this U937 membrane substrate. Consistent with this, the ϳ10-fold reduction in the degree of partitioning when comparing compounds 1 and 2 is in close agreement to the 13-fold difference expected based on the K I * app and IC 50 values. These same trends were observed with analogs with even shorter alkyl chains (compounds 3 and 4) . As shown in Table II , the C-4 and C-6 analogs were even less potent than compound 2 when using the radiolabeled membranes from U937 cells as 5 The partition coefficient, C, is defined as the concentration (molarity) of inhibitor in the phospholipid bilayer divided by the concentration in the aqueous phase. a Ratio of the rate in the absence to that in the presence of compound 1.
b Reaction volumes could not be less than 1 ml due to phospholipid solubility problems. 3 H]arachidonate-labeled membranes from U937 cells. Conditions were identical to those for the assay of with these membranes as substrate. The samples were then centrifuged to remove the membranes, and the concentration of inhibitor in the aqueous phase was determined by measuring the absorbance at 280 nm (⑀ 280 ϭ 1.8 and 1.7 mM Ϫ1 cm Ϫ1 for compounds 1 and 2, respectively). Membrane concentrations are expressed as the bulk concentration of phospholipid: closed circles, compound 1; open circles, compound 2. The solid lines are a computer fit to a partial partitioning assuming that the amount of inhibitor in the bilayer is the difference between the total amount of inhibitor present and the amount of inhibitor remaining in solution.
substrate. Undoubtedly, these analogs partition even less effectively into the cellular membranes. In fact, these analogs were only partially partitioned into the covesicle substrate: Fig.  6 shows that the inhibition of the enzyme by the C-4 analog when using the covesicle substrate is dependent on the reaction volume. A partition coefficient of 200 was determined using a nonlinear regression analysis to fit the data to the following
where L is the volume of the reaction mixture; P and I T are the mole amounts of phospholipid and inhibitor, respectively; C is the partition coefficient 5 ; M is a constant 6 ; U is the volume that the bilayer occupies (equal to 1.21 ϫ 10 Ϫ6 ml/nmol; see Ref.
43); and (v 0 )
o /(v 0 ) I is as defined earlier. After taking this partial partitioning into account, it can be seen in Table II that these shorter-chained analogs have very small K I * app values. It is obviously the case, therefore, that the greatly reduced IC 50 for the C-4 analog when using the radiolabeled U937 membrane substrate, for example, results from an extremely poor partitioning of the inhibitor into this membrane substrate. This is despite the inhibitor having an intrinsic dissociation constant from the active site (K I * app ) more than 600 times smaller than the K m * app . Effects of Aqueous Aggregation on Inhibition-Another example of the effect of partitioning on the inhibition, albeit from a different mechanism, is seen with the amine and sulfoxide analogs, compounds 5 and 6. These compounds do not effectively inhibit the cPLA 2 when using either the [ 3 H]arachidonate-labeled membranes from U937 cells or the 14 C-PAPC/ DMPM covesicles as substrate if the compounds are added as aqueous solutions to the assay. However, if the inhibitors are added as organic solutions (CHCl 3 ) during the preparation of the 14 C-PAPC/DMPM covesicles, it could be shown that they both dose-dependently inhibited the enzyme. As shown in These results suggest that compounds 5 and 6 are able to inhibit the enzyme when present within the bilayer. The lack of inhibition observed when these compounds were added as aqueous solutions may be explained by an inability to partition into the bilayer. This was verified by the use of differential scanning calorimetry to measure the effect of the compounds on the phase transition of DMPM vesicles. Consistent with the complete partitioning of compound 2 as described above, the addition of greater amounts of a solution of compound 2 resulted in the progressive lowering and broadening of the phase transition temperature. Moreover, the same broadening and lowering occurs regardless of whether the inhibitor was added as an aqueous solution to preformed vesicles, or if the vesicles were formed in the presence of inhibitor to ensure bilayer incorporation (results not shown).
However, neither compound 5 nor compound 6 added as an aqueous solution to preformed vesicles was able to cause a lowering and broadening of the phase transition temperature characteristic of membrane partitioning. Only when these vesicles were prepared with the inhibitors present were these changes observed (results not shown). These differential scanning calorimetry measurements, therefore, provide definitive evidence that the amine and sulfoxide analogs are not able to partition into bilayers when added as aqueous solutions. An explanation for this may be that compounds 5 and 6 form 6 In Equation 2, M is defined as follows,
where I T equals the total mole amount of inhibitor present. All other variables are defined in the text. aggregates in solution, which prevents the transfer of monomers of inhibitor into the phospholipid bilayer. Indeed, these inhibitors have critical aggregation concentration (CAC) 7 values in the nanomolar range (see Table III ). However, this cannot fully account for the lack of partitioning because the quaternary ammonium inhibitors 1 and 2 also have small CAC values that are considerably below their respective IC 50 values. DISCUSSION We have shown that choline derivatives 1-4 inhibit cPLA 2 at the interface in a manner that is competitive with respect to phospholipid molecules for the active site. Inhibitors that act at the interface will always show inhibition because the enzyme must be at the interface in order to hydrolyze the phospholipid. Inhibitors of this type may be pharmacologically advantageous in vivo as compared with inhibitors that act on the enzyme in the aqueous phase, because the degree of inhibition for the latter will depend on the fraction of enzyme bound to the interface.
Although these choline derivatives were also shown to partition into phospholipid bilayers when added as aqueous solutions, it was surprising that the amine and sulfoxide analogs, compounds 5 and 6, could not partition in the same way. This was not the result of the choline analogs being monomeric because the critical micelle concentration values for compounds 1 and 2 were well below the concentrations needed for inhibition of the enzyme. Because the aggregates formed by the amine and sulfoxide analogs involve hydrogen bonding or dipole-dipole interactions, respectively, between "head groups" of neighboring molecules, it may be that the strength of the aggregates prevents effective partitioning. With the choline derivatives, which cannot provide for dipole-dipole or hydrogen bonding interactions between neighboring head groups, the aggregates may not be as strong.
Shortening the n-alkyl chain of compound 1 considerably diminishes the percentage of inhibitor partitioned into the phospholipid bilayer. This presumably results from a less energetic hydrophobic interaction between the shorter alkyl chain and the fatty acid tails of the phospholipids making up the bilayer. These shorter-chained analogs also provide direct evidence for the idea that molecules that have comparable affinities for the active site do not necessarily have comparable active site dissociation constants. That is, the value of a dissociation constant at the interface (K I * app ) is a measure of the relative affinity of the molecule for the active site as compared with the affinity of the molecule for the bilayer (44). Thus, two molecules which interact identically with the active site may have different dissociation constants if one interacts more strongly with the bilayer (41) . In the case of the chain length analogs of compound 1, for example, the shorter-chained analogs do not interact as strongly with the bilayer as compared with the analogs with longer chains. This is evidenced by the fact that shorter-chained analogs partition to a much smaller extent into the bilayer. Therefore, it is easier for the enzyme to "extract" these from the bilayer. Thus, the decreased interaction with the bilayer contributes to the lower K I * app values determined for these shorter-chained analogs and may be the sole reason for the smaller dissociation constant.
These molecules represent an important step in the develop- 7 The CAC is the concentration at which light scattering intensity increased to and maintained a value Ն 0.1 V over background intensity at 90°detection. The CAC may equal the critical micelle concentration, but verification that these compounds indeed formed micelles was not obtained. b Determined after correcting for partitioning. See text for details. c The partition coefficient, C, is defined as the concentration (molarity) of inhibitor in the phospholipid bilayer divided by the concentration in the aqueous phase. Determined according to the procedure detailed in Fig. 6 and the text. ment of potent in vivo inhibitors of cPLA 2 because they inhibit the enzyme at the interface and provide for only weak interactions with the phospholipid bilayer. In this regard, inhibitors such as the shorter-chained analogs, which have a strong affinity for the active site but partition very poorly into the bilayer, may seem to be poor inhibitors in terms of bulk inhibitor concentration in an in vitro assay. This is because a small fraction of the inhibitor would be present in the bilayer because the ratio of the volumes of the bilayer to the aqueous phase is low (ϳ10 Ϫ5 ). However, as reviewed by Gelb et al. (25) , a much larger fraction of the inhibitor would be present in the bilayer in vivo because the ratio of the lipid to aqueous volumes is about 0.1. Thus, a poorly partioned inhibitor in vitro may prove to be very potent in vivo. We are now actively testing these ideas in our laboratory in order to determine the attributes of a cPLA 2 inhibitor that will yield a clinically active antiinflammatory agent.
